Empagliflozin Adjunct With Insulin Pump Therapy Enhanced Glycemic Control and β-Cell Function in Patients With Long-Standing Type 2 Diabetes
AACE Endocrinology and Diabetes · 2026-04
DOI: 10.1016/j.aed.2026.03.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift AACE Endocrinology and Diabetes, 2026-04. Verfasst von Soobong Choi. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
Empagliflozin, a selective sodium-glucose cotransporter 2 inhibitor, improves glycemic control and insulin resistance in type 2 diabetes (T2D). This study evaluated the effectiveness of adjunct empagliflozin on glycemic control and β-cell function in patients with long-standing, inadequately controlled T2D despite insulin pump therapy.
Methods
In this single-center observational study, 103 patients (mean age 61.8 years; diabetes duration 17.8 years; pump duration 4.0 years) with inadequate control (HbA1c 6.6–14.3%) received 10 mg once-daily empagliflozin for six months. The primary endpoint was the change in HbA1c from baseline. Secondary endpoints included changes in C-peptidogenic index, Matsuda index (MI), disposition index (DI), total daily insulin dose (TDD), BMI, and serum creatinine.
Results
Data from 103 patients (mean follow-up 5.8 months) were analyzed. HbA1c significantly decreased from 7.82 ± 1.14% at baseline to 6.98 ± 0.92% (p < 0.001). β-cell function, assessed via the C-peptidogenic index and DI, significantly increased (p < 0.05), while TDD significantly decreased (p < 0.05). BMI and serum creatinine remained unchanged throughout the observation period. No DKA or frequent hypoglycemia occurred.
Conclusion
Adjunctive once-daily 10 mg empagliflozin significantly improved glycemic control and β-cell function while reducing total insulin requirements in patients with long-standing T2D inadequately controlled by insulin pump therapy alone. Notably, these benefits were achieved without significant changes in BMI or renal function.
Zitieren
APA
Choi, S. (2026). Empagliflozin Adjunct With Insulin Pump Therapy Enhanced Glycemic Control and β-Cell Function in Patients With Long-Standing Type 2 Diabetes. AACE Endocrinology and Diabetes. https://doi.org/10.1016/j.aed.2026.03.010
Vancouver
Choi S. Empagliflozin Adjunct With Insulin Pump Therapy Enhanced Glycemic Control and β-Cell Function in Patients With Long-Standing Type 2 Diabetes. AACE Endocrinology and Diabetes. 2026. doi:10.1016/j.aed.2026.03.010
BibTeX
@article{Choi2026,
author = {Choi, Soobong},
title = {Empagliflozin Adjunct With Insulin Pump Therapy Enhanced Glycemic Control and β-Cell Function in Patients With Long-Standing Type 2 Diabetes},
journal = {AACE Endocrinology and Diabetes},
year = {2026},
doi = {10.1016/j.aed.2026.03.010}
}
EUVIMED